Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influsplit
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Influsplit is an influenza vaccine developed by GlaxoSmithKline (GSK) Biologicals. It is available in trivalent (Influsplit SSW) and quadrivalent (Influsplit Tetra) formulations, containing inactivated influenza virus strains recommended for specific seasons. The vaccine works by stimulating the immune system to produce antibodies and T-cells against these influenza virus antigens, thereby providing protection against influenza infections.
- Brand names
- FluarixFluarix TetraInflusplit SSWInflusplit Tetra
- Other names
- INFLUSPLIT TETRA
02
Targets
Flu (Influenza surface proteins)
Beyond the preview
Go deeper on Influsplit.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influsplit.